<SEC-DOCUMENT>0001376339-22-000081.txt : 20220518
<SEC-HEADER>0001376339-22-000081.hdr.sgml : 20220518
<ACCEPTANCE-DATETIME>20220518162634
ACCESSION NUMBER:		0001376339-22-000081
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20220518
DATE AS OF CHANGE:		20220518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		22939477

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>a20220518defa14apressrelea.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i30a5322147c841b2b804cc2fab105caa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 14A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Rule&#160;14a-101)</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION REQUIRED IN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROXY STATEMENT</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE 14A INFORMATION</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proxy Statement Pursuant to Section&#160;14(a) of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by the registrant&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Filed by a party other than the registrant&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box&#58;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:21.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:472.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary Proxy Statement</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential, for use of the Commission only (as permitted by Rule&#160;14a-6(e)(2))</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Proxy Statement</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definitive Additional Materials</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting Material Pursuant to &#167;240.14a-12</font></td></tr></table></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%">MIMEDX GROUP, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name of registrant as specified in its charter)</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of the filing fee (check the appropriate box)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No fee required.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class of securities to which transaction applies&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate number of securities to which transaction applies&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&#160;0-11 (set forth the amount on which the filing fee is calculated and state how it was determined)&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proposed maximum aggregate value of transaction&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fee paid&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee paid previously with preliminary materials.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="9" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check box if any part of the fee is offset as provided by Exchange Act Rule&#160;0-11(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount previously paid&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form, Schedule or Registration Statement No.&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing party&#58;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</font></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="border-bottom:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-top:1pt solid #828282;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #828282;border-left:1pt solid #828282;border-right:1pt solid #828282;border-top:1pt solid #828282;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date filed&#58;</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i30a5322147c841b2b804cc2fab105caa_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, the Registrant published a Press Release as set forth below&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Established Strong, New Foundation for Growth</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Company Urges Shareholders to Vote &#8220;FOR&#8221; Both Highly Qualified Director Nominees &#8211; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">James L. Bierman and Phyllis Gardner, M.D. &#8211; on the WHITE Proxy Card</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">MARIETTA, Ga., May 18, 2022 &#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> MiMedx Group, Inc. (NASDAQ&#58; MDXG) (&#8220;MIMEDX&#8221; or the &#8220;Company&#8221;), a transformational placental biologics company, today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 Annual Meeting of Shareholders, which is scheduled to be held on June 7, 2022. The presentation, and other important shareholder materials, are available at </font><font style="color:#0094ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">www.VoteMIMEDX.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the presentation, MIMEDX outlines the significant progress the Company has made over the last three years under its current leadership team and provides transparency around a number of topics and initiatives pertinent to shareholders, including&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:14.15pt">Strategy for Long-Term Value Creation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> MIMEDX has taken decisive action to successfully sustain, stabilize and grow the Company over the last three years, and has a clear strategy for long-term shareholder value creation. MIMEDX recently announced a third consecutive quarter of double-digit growth in its Advanced Wound Care &#38; Surgical Recovery products, demonstrating strong execution. In addition, the realignment of the Company&#8217;s internal business structure positions MIMEDX to further expand, innovate, and drive sustained growth, and also accelerate the start of trial enrollment in its Knee Osteoarthritis clinical trial program.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:14.15pt">Corporate Governance Practices and Board Qualifications&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> MIMEDX&#8217;s Board has been entirely reconstituted since 2019 and is made up of nine highly qualified directors with the critical skills, life-sciences experience and business acumen to oversee the Company&#8217;s strategy. The Board has adopted approximately 70 best-practice and shareholder friendly corporate governance reforms over the last three years and resolved all legacy Company issues, demonstrating its commitment to best-in-class governance practices.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:14.15pt">Executive Compensation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> MIMEDX&#8217;s executive compensation, determined in partnership with an independent consultant, is based on a philosophy of organizational and individual performance and is aligned with shareholder value through performance factors, including revenue growth, and significant equity-based portions of total compensation. It is well within the range of MIMEDX peers and is closely aligned with shareholder interests. For example, in part due to the decline in the Company&#8217;s stock price, none of MIMEDX&#8217;s executive officers received annual cash bonuses at their 2021 target levels. </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About MIMEDX</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Important Cautionary Statement </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release includes forward-looking statements. Statements regarding&#58; (i) our belief that the long term strategy we have chosen is in the best interests of our shareholders&#59;  (ii) our belief that as we continue to execute against our stated objectives and navigate our next phase of growth, we are well positioned for the future&#59;  and (iii) our belief that the experience, expertise and commitment of the MIMEDX leadership team, as overseen by our Board of Directors, will help position the Company for further future success and value creation. Additional forward-looking statements may be identified by words such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;plan,&#34; &#8220;goal,&#8221; &#8220;outlook,&#8221; &#34;potential,&#34; &#34;will,&#34; &#34;preliminary,&#34; and similar expressions, and are based on management's current beliefs and expectations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include&#58; (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors&#59; (ii) the status, timing, results and expected results of the Company&#8217;s clinical trials, planned regulatory submissions and regulatory approvals, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with Current Good Manufacturing Practices (CGMP) and appropriate chemistry and manufacturing controls&#59; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements&#59; (iv) our access to hospitals and health care provider facilities could be restricted as a result of the ongoing COVID-19 pandemic or other factors&#59; (v) the results of scientific research are uncertain and may have little or no value&#59; (vi) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, regulatory approvals, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship&#59; (vii) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies&#59; and (viii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Important Additional Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company, its directors, director nominees and certain of its executive officers are participants in the solicitation of proxies from the Company&#8217;s shareholders in connection with the 2022 annual meeting of shareholders (the &#8220;2022 Annual Meeting&#8221;). The Company has filed a definitive proxy statement and a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">WHITE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> proxy card with the Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with any such solicitation of proxies from the Company&#8217;s shareholders. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">WHITE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. The Company&#8217;s definitive proxy statement for the 2022 Annual Meeting contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company&#8217;s directors, director nominees and executive officers in the matters to be acted upon at the 2022 Annual Meeting. Information regarding subsequent changes to their holdings of the Company&#8217;s securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company&#8217;s website at www.mimedx.com or through the SEC&#8217;s website at www.sec.gov. Information can also be found in the Company&#8217;s other SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021. Shareholders are able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC&#8217;s website at www.sec.gov. Copies are also available at no charge on the Company&#8217;s website at www.mimedx.com. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Contacts</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Investors&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Jack Howarth</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">404-360-5681</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">jhowarth&#64;mimedx.com</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Media&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Hilary Dixon</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Corporate &#38; Strategic Communications</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">404-323-4779</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">hdixon&#64;mimedx.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
